Literature DB >> 17720034

Treatment-resistant schizophrenia.

Helio Elkis1.   

Abstract

This article opens with a brief history of pharmacologic treatment of schizophrenia. It then discusses the definition and treatment of treatment-resistant schizophrenia, with particular attention to clinical, biological and neuroimaging correlates, as well as the best treatment options, including the use of clozapine in patients who meet the definition of treatment-resistant schizophrenia.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17720034     DOI： 10.1016/j.psc.2007.04.001

Source DB:  PubMed          Journal:  Psychiatr Clin North Am        ISSN： 0193-953X


  35 in total

Review 1.  MicroRNAs in Schizophrenia: Implications for Synaptic Plasticity and Dopamine-Glutamate Interaction at the Postsynaptic Density. New Avenues for Antipsychotic Treatment Under a Theranostic Perspective.

Authors:  Andrea de Bartolomeis; Felice Iasevoli; Carmine Tomasetti; Elisabetta F Buonaguro
Journal:  Mol Neurobiol       Date:  2014-11-14       Impact factor: 5.590

2.  Clozapine: a distinct, poorly understood and under-used molecule.

Authors:  Ridha Joober; Patricia Boksa
Journal:  J Psychiatry Neurosci       Date:  2010-05       Impact factor: 6.186

Review 3.  Functional connectivity as a means to delineate differences between treatment-resistant and treatment-responsive schizophrenia.

Authors:  Sara Paul; Nathan Sharfman
Journal:  J Neurophysiol       Date:  2016-01-13       Impact factor: 2.714

Review 4.  Progress in defining optimal treatment outcome in schizophrenia.

Authors:  Gary Remington; George Foussias; Ofer Agid
Journal:  CNS Drugs       Date:  2010-01       Impact factor: 5.749

5.  Synchronizing theta oscillations with direct-current stimulation strengthens adaptive control in the human brain.

Authors:  Robert M G Reinhart; Julia Zhu; Sohee Park; Geoffrey F Woodman
Journal:  Proc Natl Acad Sci U S A       Date:  2015-06-29       Impact factor: 11.205

Review 6.  Treatment resistant schizophrenia: Clinical, biological, and therapeutic perspectives.

Authors:  Frederick C Nucifora; Edgar Woznica; Brian J Lee; Nicola Cascella; Akira Sawa
Journal:  Neurobiol Dis       Date:  2018-08-29       Impact factor: 5.996

7.  Clinical response in a risperidone-medicated naturalistic sample: patients' characteristics and dose-dependent pharmacokinetic patterns.

Authors:  Michael Paulzen; Ekkehard Haen; Benedikt Stegmann; Stefan Unterecker; Christoph Hiemke; Gerhard Gründer; Georgios Schoretsanitis
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2016-10-01       Impact factor: 5.270

8.  Sensitivity of the Positive and Negative Syndrome Scale (PANSS) in Detecting Treatment Effects via Network Analysis.

Authors:  Farnaz Zamani Esfahlani; Hiroki Sayama; Katherine Frost Visser; Gregory P Strauss
Journal:  Innov Clin Neurosci       Date:  2017-12-01

9.  Adjunctive use of lithium carbonate for the management of neutropenia in clozapine-treated children.

Authors:  Anand Mattai; Lawrence Fung; Jennifer Bakalar; Gerald Overman; Julia Tossell; Rachel Miller; Judith Rapoport; Nitin Gogtay
Journal:  Hum Psychopharmacol       Date:  2009-10       Impact factor: 1.672

10.  Current perspectives in the treatment of resistant schizophrenia.

Authors:  R K Solanki; Paramjeet Singh; Deepti Munshi
Journal:  Indian J Psychiatry       Date:  2009 Oct-Dec       Impact factor: 1.759
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.